FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 667 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Asciminib NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable for Reaching High-Risk and Underserved Populations ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer... MOST POPULAR On legacy giving: “It allows me to give something more meaningful... October 13, 2021 Cancer in My Community: Working to Eliminate the Stigma of Cancer... September 14, 2021 Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Load more HOT NEWS Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... EMA Recommends Granting a Marketing Authorisation for Vorasidenib Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours From smart knives to virtual reality tumours: five innovations in understanding...
